|
 |
ULTRAVISTThis page contains recent news articles, when available, and an overview of ULTRAVIST but does not offer medical advice. You should contact your physician with regard to any health issues or concerns.Perera said he sought a local supplier, Brodies, which supplied Ultravist, a contrast media used all over the country by private hospitals for years. ... The Reporter Belize Showdown at Commission of Inquiry – Fabro maintains innocence; Sosa says ... - Dec 23, 2009 It had been rumored in certain circles that Dr. Ghazy had stood up to management over the purchase of the Ultravist brand of contrast media for usage in CT ... Amandala ПоликлиничеÑ?каÑ? Ñ?мерть - Dec 10, 2009 Еще на Ñ?тадии подготовки к обÑ?ледованию, во времÑ? введениÑ? рентгеноконтраÑ?тного Ñ?редÑ?тва Ultravist через капельницу Ñ?удье Ñ?тало плохо — в ее организме, ... Коммерсантъ Reliability of positron emission tomography–computed tomography in ... - Oct 19, 2009 Images (7.5 mm thick) were obtained with sections after intravenous injection of 60 to 100 mL of contrast material (Ultravist 300; Bayer Schering Pharma, ... The Journal of Thoracic and Cardiovascular Surgery Schering says Ultravist recall could reduce co value by 0.74 eur/shr ... - Jul 31, 2006 BERLIN (AFX) - Schering AG said it is voluntarily recalling its Ultravist X-ray contrast agent because of potential safety issues, a move that could reduce ... Forbes Schering, Siemens to evaluate new computer tomography technology - Nov 28, 2005 ...they will jointly evaluate the potential of Siemens' new Dual Source Computer Tomography (CT) in combination with Schering's CT imaging agent Ultravist. ... Forbes Berlex Voluntarily Recalls Ultravist(R) Injection 370 mgI/mL. - Jul 31, 2006 WAYNE, NJ, July 31 /PRNewswire-FirstCall/ -- Berlex, Inc., a US affiliate of Schering AG, Germany, is voluntarily recalling all lots of its X-ray contrast ... Free with registration - PR Newswire - AccessMyLibrary.com German shares close down on weak Wall Street, E.ON slide UPDATE - Jul 31, 2006 Bayer slipped 0.53 to 38.57 after Schering said it is voluntarily recalling its Ultravist X-ray contrast agent because of potential safety issues -- a move ... Forbes … Issues Nationwide Recall Of A Single Lot Of Ultravist(R) Injection... - Jul 23, 2006 Berlex, Inc. has initiated a nationwide recall of a single lot (No. 41500A) of its intravenous X-ray contrast agent, Ultravist(R) Injection 370 mgI/mL, ... Medical News Today - Medical News Today (press release) Berlex Updates Ultravist Recall - Aug 2, 2006 Berlex has updated its Ultravist (iopromide) injection recall to include all lots of the 370 mgI/mL x-ray contrast agent due to the potential presence of ... Facts and Comparisons Scientia Veritas announces updates in stroke management. - Feb 9, 2005 The company's most important contrast media are Iopamiron and Ultravist. Both are nonionic products used in a wide range of indications in computer ... Free with registration - Asia Africa Intelligence Wire - AccessMyLibrary.com Berlex Recalls Singe Lot of Ultravist - Jul 26, 2006 Berlex has issued a voluntary nationwide recall of a single lot (No. 41500A, date 1/2007) of its intravenous x-ray contrast agent Ultravist (iopromide) 370 ... Facts and Comparisons … Issues Nationwide Recall of a Single Lot of Ultravist(R) Injection... - Jul 20, 2006 WAYNE, NJ, July 20 /PRNewswire/ -- Berlex, Inc. has initiated a nationwide recall of a single lot (No. 41500A) of its intravenous X-ray contrast agent, ... $4.95 - PR Newswire - ECNext Press Release: Schering Voluntarily Recalls Ultravist(R) Injection... - Jul 31, 2006 Schering Voluntarily Recalls Ultravist(R) Injection 370 mgI/ml. from PR Newswire. Highbeam Research – FREE Trial. Pay-Per-View - PR Newswire - HighBeam Research … Issues Nationwide Recall of a Single Lot of Ultravist(R) Injection... - Jul 20, 2006 Berlex Issues Nationwide Recall of a Single Lot of Ultravist(R) Injection 370 mgI/mL, 125 mL in the US from PR Newswire. Highbeam Research – FREE Trial. Pay-Per-View - PR Newswire - HighBeam Research Bayer HealthCare Pharmaceuticals, Amerinet Extend Contrast Media … - Apr 8, 2008 Ultravist will be available in four concentrations (150, 240, 300 and 370 mgI) ... In the United States, Ultravist is available in a variety of vial sizes, ... RedOrbit Dax braucht etwas Erholung - Nov 29, 2005 Damit könnte SF-64 in etwa genau so viel erlösen wie die Kontrastmittel Magnevist und Ultravist. Im Zuge seines Umbaus will der Chemie-Konzern Degussa ... ARD Schering zieht Bayer runter - Jul 31, 2006 Denn der Rückruf des Röntgenkontrastmittels Ultravist 370 könnte die Erlöse ... Ultravist wird Patienten vor allem bei der Computertomographie injiziert. ... ARD Schering AG und Siemens Medical Solutions erforschen gemeinsam … - Nov 28, 2005 Ultravist ist ein intravaskuläres, nicht-ionisches und für alle gängigen ... Ãœber neue Anwendungen für bewährte Kontrastmittel wie Ultravist hinaus eröffnet ... pressrelations.de Schering and Siemens to explore new applications for dual-source CT … - Dec 5, 2005 Ultravist is an intravascular, non-ionic contrast medium suitable for all common ... "The combination of Dual Source CT imaging performance and Ultravist is ... MTBeurope Bayer Schering Pharma AG / Interim Announcement - Sep 5, 2007 In the Diagnostic Imaging business unit, sales of Magnevist® rose, while those of Ultravist® fell markedly from the prior-year quarter. ... Handelsblatt Berlex, Amerinet Extend and Enhance Agreement for Contrast Media. - Jan 20, 2006 Ultravist is a nonionic, iodinated, low osmolar radiological contrast agent ... Introduced in Europe in 1985, and in the US in 1995, Ultravist is being used ... Free with registration - PR Newswire - AccessMyLibrary.com Press Release: Schering AG and Siemens Medical Solutions to Jointly … - Nov 28, 2005 Ultravist is an intravascular, non-ionic contrast medium suitable for all common ... "The combination of Dual Source CT imaging performance and Ultravist is ... Pay-Per-View - PR Newswire - HighBeam Research Press Release: Bayer HealthCare Pharmaceuticals, Amerinet Extend … - Apr 8, 2008 Magnevist(R) and Ultravist(R) are part of Amerinet's Portfolio of Contracted Contrast ... Ultravist will be available in four concentrations (150, 240, ... Pay-Per-View - PR Newswire - HighBeam Research Press Release: Berlex, Premier Sign New Agreement for Magnetic … - May 2, 2005 Article: BERLEX RECEIVES FDA MARKET CLEARANCE FOR ULTRAVIST ... ... General Manager, Imaging, Berlex Laboratories. ULTRAVIST injection ... ... Pay-Per-View - PR Newswire - HighBeam Research KPMG traut Schering Gewinnsprung zu - Aug 5, 2006 Mit der Ultravist-Produktfamilie kam Schering im vergangenen Jahr auf einen ... Damit war Ultravist das gemessen am Umsatz viertstärkste Schering-Präparat. ... Berliner Morgenpost Press Release: Berlex, Amerinet Extend and Enhance Agreement for … - Jan 20, 2006 Ultravist(R) Joins Magnevist(R) as part of Amerinet's Portfolio of Contracted Contrast ... Article: Berlex Voluntarily Recalls Ultravist(R) Injection 370 . ... Pay-Per-View - PR Newswire - HighBeam Research euro adhoc: Bayer Schering Pharma AG - Apr 28, 2008 In the Diagnostic Imaging business unit, sales of Ultravist® grew, although prior-year sales were depressed by temporary interruption of the distribution of ... presseportal.de Press Release: Berlex, Premier Sign New Agreement for Magnetic … - Jan 4, 2007 In all markets, the Berlex sales force will provide technical ... and Ultravist in the U.S. Berlex will continue to manufacture ... paramagnetic contrast ... Pay-Per-View - PR Newswire - HighBeam Research Press Release: /CORRECTION -- Berlex, Inc./. - PR Newswire | … - Jul 21, 2006 Berlex Issues Nationwide Recall of a Single Lot of Ultravist(R) ... 41500A) of its intravenous X-ray contrast agent, Ultravist injection 370 mgI/mL, 125 mL, ... Pay-Per-View - PR Newswire - HighBeam Research Philips, Schering tie up in new disease diagnosis - Nov 28, 2005 Ultravist had sales of 236 million euros last year and Magnevist had sales of 303 million euros. The firms plan to expand the alliance to cover other ... RedOrbit Event Brief of Q3 2006 Bayer Earnings Conference Call - Part 2. - Nov 27, 2006 So this EUR240 million are the major difference, and they are compensated by EUR33 million in Ultravist because this Ultravist (technical difficulty) ... Free with registration - America's Intelligence Wire - AccessMyLibrary.com Schering AG i Siemens Medical Solutions Å‚Ä…czÄ… siÅ‚y w badaniach nad … - Nov 28, 2005 Ultravist to dożylny, niejonowy Å›rodek kontrastowy używany powszechnie w różnego rodzaju badaniach rentgenowskich. Jest dopuszczony do stosowania w ponad ... eGospodarka Risk of contrast-induced nephropathy in patients with normal renal … - Jan 12, 2007 Oslo, Norway) or the nonionic, low-osmolar, monomeric agent iopromide (Ultravist ® , Bayer Schering Pharma, Germany), for coronary angiography. ... Nature.com Long-term effects of repeated autologous transplantation of bone... - Aug 11, 2008 ...pedal arteries after administration of a single bolus of 2 mg/kg of body weight (Ultravist 370, Schering, Berlin, Germany) at a flow rate of 3.5 ml/s. ... Nature.com Event Brief of Q2 2006 Bayer Earnings Conference Call - Part 2. - Aug 29, 2006 We took also into consideration the Ultravist effect of -- the estimate, or best estimation on the Ultravist effect in this year. There is no phasing issue ... Free with registration - America's Intelligence Wire - AccessMyLibrary.com ePT@PharmTech.com - Sep 1, 2006 The recall does not include other concentrations of Ultravist. id=362360. [A] Aegis Therapeutics (San Diego, CA) launches a new formulation technology to ... Free with registration - Pharmaceutical Technology - AccessMyLibrary.com 大涨å?Žå›žè°ƒæ¬§é™†è‚¡å¸‚å°?幅跌收 - Aug 1, 2006 ...拜耳指出，上述事件å?¯èƒ½åŽ‹åˆ¶å…ˆç?µçš„股价，毕马å¨?估计å?¬å›žUltravist将对先ç?µçš„è‚¡ä»· 产生0.74欧元的影å“?。但是，今天拜耳没有æ??供对先ç?µç»ˆæ¢å…‹éš†æ°?症试验所产生影å“?的估计 ... 新浪网 Novice.Dnevnik.si Tiskane izdaje/Moje zdravje - Jan 22, 2008 Med CT-kontrastnimi sredstvi je najpomembnejÅ¡i jopromid (ultravist), ki ga uporabljajo po vsem svetu. Ta namreÄ? omogoÄ?a prikaz ven in arterij ter odkriva ... Dnevnik/si Article: 3Q Profits Rise at Merck, Schering-Plough - AP Online |... - Oct 24, 2005 Article: Schering Voluntarily Recalls Ultravist(R) Injection 370 ... PR Newswire; July 31, ... Schering is undertaking this recall of Ultravist ... ... Pay-Per-View - AP Online - HighBeam Research Bayer's Nexavar and Xarelto key to future growth - Nov 9, 2007 ...with sales in its pharmaceutical division rising 8% thanks to growth from the Yasmin contraceptive pill franchise, Mirena, Ultravist and Nexavar. ... Pharmafocus Intracranial Solitary Fibrous Tumors: Imaging Findings in 6 Consecutiv... - Jan 8, 2007 The enhanced scans were obtained with the injection of 150 mL of iopromide (Ultravist 300; Schering, Seoul, Korea); 100 mL was injected as a bolus before ... AJNR (subscription) Evaluation of Varicose Veins May be Improved with 3-D CT Scans - Oct 2, 2008 ...age 54.9) who had visible varicose veins and scanned their legs with three-dimensional CT using a nonionic contrast material, iopromide (Ultravist). ... MedPage Today Bayer expects a record year in 2007 - Nov 11, 2007 The main growth drivers were the Yasmin® product family along with Mirena®, Ultravist® and Nexavar®. Sales in the Consumer Health segment amounted to EUR ... webwire.com Optimized Contrast-Enhanced CT Protocols for Diagnostic Whole-Body … - Jun 1, 2008 Single-phase protocols included an intravenous contrast–enhanced (Ultravist 370; iodine at 370 mg/mL) single-phase whole-body CT scan (90 mL at 1.8 mL/min; ... Journal of Nuclear Medicine (subscriptio... Bayer beats forecasts, helped by a tax gain, and leads markets higher. - Nov 12, 2007 ...with Mirena (levonorgestrel), the contrast media Ultravist and the cancer drug Nexavar (sorafenib), turnover of which doubled to 76.0 million euros. ... Free with registration - Pharma Marketletter - AccessMyLibrary.com Ｘ光顯影劑德國先é?ˆè—¥å» 宣布回收 - Aug 3, 2006 ...å?°ç?£è¡›ç”Ÿç½²è—¥æ”¿è™•æŒ‡å‡ºï¼Œã€ŒUltravist三七○ã€?çš„ä¸æ–‡å“?å??為「優照ç¶æ–¯ç¢˜å?«é‡?三七○公 çµ²ï¼?公撮ã€?，是高濃度的X光顯影劑，å?¯ç”¨æ–¼å¿ƒè‡Ÿè¡€ç®¡çš„電腦斷層æ”?å½±ã€?數ä½?化減影血管 ... epochtimes.com Unternehmen: Schering trägt das Bayerkreuz - Sep 29, 2006 Die Ultravist-Panne und die gedämpften Hoffnungen platzten mitten in das Angebot von Bayer an die Schering-Aktionäre, ihre Aktien für 89 Euro zu übernehmen. ... Deutsches Ärzteblatt Der Dax pausiert - Nov 29, 2005 Damit könnte SF-64 in etwa genau so viel erlösen wie die Kontrastmittel Magnevist und Ultravist. Die Aktie legte zu Handelsbeginn um rund ein halbes Prozent ... ARD European Indexes Close Lower - Jul 31, 2006 IN Frankfurt, Bayer (BAY)(-1.51%) fell after its fresh acquisition Schering (SHR) recalled a version of it Ultravist Injection x-ray product on clotting ... BusinessWeek The Targeted Oncolytic Poxvirus JX-594 Demonstrates Antitumoral, … - Apr 10, 2007 A total of 70 ml of nonionic iodinated contrast medium (Ultravist; Schering, Ansung, Korea) was then injected. Scanning was initiated after a 5-second delay ... Nature.com German Stocks Decline on Earnings Concern; Deutsche Bank Falls - Aug 1, 2006 ...``market perform'' from ``outperform,'' citing the recall of the highest dose of Schering's Ultravist Injection x-ray product because of safety risks. ... Bloomberg Inspektor farmaceutyczny wstrzymaÅ‚ sprzedaż antybiotyku - Jan 28, 2005 Wczoraj na wniosek podlaskiego inspektora nadzoru farmaceutycznego główny inspektor farmaceutyczny wstrzymaÅ‚ sprzedaż preparatu Ultravist stosowanego do ... Gazeta.pl BAYER SCHERING PHARMA AG - Mar 1, 2008 Fludara®, Glucobay®, Magnevist®, Nimotop®, and Ultravist®. BSP's activities are focused on the unmet medical. needs of hemophilia, multiple sclerosis, ... $3,450.00 - GLOBAL INDUSTRY ANALYSTS KEY PLAYERS - Alacra Store Contrast agents may pose danger in renal disease.(Clinical Rounds)( … - Feb 1, 2007 ...to mammography significantly reduced ... and 180 seconds after injection of I mg/kg of iodine-based contrast medium (Ultravist 370, Schering, Germany). ... Pay-Per-View - Family Practice News - HighBeam Research Gewinnmitnahmen belasten Frankfurter Handel - Jul 31, 2006 Der Berliner Pharmakonzern Schering hat das Röntgenkontrastmittel Ultravist 370 zurückgerufen. Der Stoff könne im Blut von Patienten unter Umständen ... Netzeitung SUSPECTED DEATHS FROM DRUG SIDE EFFECTS UP SHARPLY IN … - Sep 7, 2007 Others that have been cited for problems are Taxotere, Ultravist and Durogesic with more than 100 side effects reported for each. ... $4.95 - AsiaPulse News - ECNext Schering in diagnostics alliances. - Nov 29, 2005 The cooperation with Siemens relates to the existing contrast medium Ultravist that Siemens is to use in new computer tomography technology. ... Pay-Per-View - Handelsblatt Wirtschafts- und Finanzzeit... - Factiva, from Dow Jones Minimally invasive sinus lifting: implant site preparation using the... - Jan 1, 2006 Slowly extend the balloon with a maximum of approximately 3 ml of radiopaque fluid (Ultravist iopromide, Berlex, Germany; or 0.9% NaCl solution). ... Free with registration - Dental Products Report Europe - AccessMyLibrary.com Stock Commentary - Europe - week to Aug 7, 2006.(financial report)( … - Jul 31, 2006 ...which it is acquiring, was withdrawing a batch of its X-ray contrast media, Ultravist (see page 6). Schering fell 1.0% overall. On the AMSTERDAM bourse, ... Free with registration - Pharma Marketletter - AccessMyLibrary.com Q2 2006 Bayer Earnings Conference Call - Part 3. - Aug 29, 2006 And the second question is to Ultravist. Obviously in the statement, I think, of Schering there was something like E40m -- sorry, E45m restructuring costs. ... Free with registration - America's Intelligence Wire - AccessMyLibrary.com Left anterior descending coronary artery dissection after blunt chest... - Nov 13, 2006 ...and intravenous injection of iopromide 370 mg (milligrams of iodine)/mL (Ultravist, Schering AG, Germany). It showed . . . [Full Text of this Article] The Journal of Thoracic and Cardiovascul... Schering "buy" - Apr 28, 2006 ...in order to develop a combination of the former's imaging agent, Ultravist, with the latter's innovative Dual Source computer tomography technology. ... newratings.com Rhabdoid Meningioma: Clinical Features and MR Imaging Findings in 15 ... - Nov 28, 2006 The enhanced scans were obtained after the injection of 150 mL of iopromide (Ultravist 300; Schering, Seoul, Korea). All of the MR examinations were ... AJNR (subscription) ALSO NOTED: YM BioSciences gets cancer drug approval in India; … - Jul 20, 2006 Berlex is recalling a single lot of its intravenous X-ray contrast agent, Ultravist Injection, due serious safety concerns related to the presence of ... FierceBiotech Stroke; Stroke diagnosis, pharma, devices, and surgical intervention ... - Mar 12, 2005 The company's most important contrast media are Iopamiron and Ultravist. Both are nonionic products used in a wide range of indications in computer ... Pay-Per-View - Obesity, Fitness & Wellness Week - Factiva, from Dow Jones Stroke; Stroke diagnosis, pharma, devices, and surgical intervention ... - Mar 7, 2005 The company's most important contrast media are Iopamiron and Ultravist. Both are nonionic products used in a wide range of indications in computer ... Pay-Per-View - Pain & Central Nervous System Week - Factiva, from Dow Jones Merger and Acquisition Scenario - Nov 25, 2006 ...sold in the United States and Canada under the Betaseron trademark (16% of net sales); Yasmin (11%); Magnevist (6%), and Ultravist (5%). ... $250.00 - Revere Reports - Revere Merger and Acquisition Scenario - Nov 25, 2006 ...sold in the United States and Canada under the Betaseron trademark (16% of net sales); Yasmin (11%); Magnevist (6%), and Ultravist (5%). ... $250.00 - Revere Reports - Revere Press Release: Scientia Veritas Announces Updates in Stroke … - Feb 9, 2005 The company's most important contrast media are Iopamiron and Ultravist. Both are nonionic products used in a wide range of indications in computer ... Pay-Per-View - PR Newswire - HighBeam Research Merger and Acquisition Scenario - Sep 2, 2006 ...sold in the United States and Canada under the Betaseron trademark (16% of net sales); Yasmin (11%); Magnevist (6%), and Ultravist (5%). ... $250.00 - Revere Reports - Revere Article: Moldova says relations with Ukraine unchanged despite … - Sep 8, 2005 The Executive Board of Bayer AG informed Schering AG today that this offer remains unchanged despite the recall of Ultravist 370 mgI/ml and the sargramostim ... Pay-Per-View - AP Worldstream - HighBeam Research Merger and Acquisition Scenario - Nov 25, 2006 ...sold in the United States and Canada under the Betaseron trademark (16% of net sales); Yasmin (11%); Magnevist (6%), and Ultravist (5%). ... $250.00 - Revere Reports - Revere Merger and Acquisition Scenario - Nov 25, 2006 ...sold in the United States and Canada under the Betaseron trademark (16% of net sales); Yasmin (11%); Magnevist (6%), and Ultravist (5%). ... $250.00 - Revere Reports - Revere Merger and Acquisition Scenario - Nov 25, 2006 ...sold in the United States and Canada under the Betaseron trademark (16% of net sales); Yasmin (11%); Magnevist (6%), and Ultravist (5%). ... $250.00 - Revere Reports - Revere Merger and Acquisition Scenario - Nov 25, 2006 ...sold in the United States and Canada under the Betaseron trademark (16% of net sales); Yasmin (11%); Magnevist (6%), and Ultravist (5%). ... $250.00 - Revere Reports - Revere Merger and Acquisition Scenario - Nov 25, 2006 ...sold in the United States and Canada under the Betaseron trademark (16% of net sales); Yasmin (11%); Magnevist (6%), and Ultravist (5%). ... $250.00 - Revere Reports - Revere Merger and Acquisition Scenario - Nov 25, 2006 ...sold in the United States and Canada under the Betaseron trademark (16% of net sales); Yasmin (11%); Magnevist (6%), and Ultravist (5%). ... $250.00 - Revere Reports - Revere Merger and Acquisition Scenario - Nov 25, 2006 ...sold in the United States and Canada under the Betaseron trademark (16% of net sales); Yasmin (11%); Magnevist (6%), and Ultravist (5%). ... $250.00 - Revere Reports - Revere Merger and Acquisition Scenario - Nov 25, 2006 ...sold in the United States and Canada under the Betaseron trademark (16% of net sales); Yasmin (11%); Magnevist (6%), and Ultravist (5%). ... $250.00 - Revere Reports - Revere Merger and Acquisition Scenario - Nov 4, 2006 ...sold in the United States and Canada under the Betaseron trademark (16% of net sales); Yasmin (11%); Magnevist (6%), and Ultravist (5%). ... $250.00 - Revere Reports - Revere Merger and Acquisition Scenario - Nov 25, 2006 ...sold in the United States and Canada under the Betaseron trademark (16% of net sales); Yasmin (11%); Magnevist (6%), and Ultravist (5%). ... $250.00 - Revere Reports - Revere Merger and Acquisition Scenario - Oct 28, 2006 ...sold in the United States and Canada under the Betaseron trademark (16% of net sales); Yasmin (11%); Magnevist (6%), and Ultravist (5%). ... $250.00 - Revere Reports - Revere Merger and Acquisition Scenario - Nov 25, 2006 ...sold in the United States and Canada under the Betaseron trademark (16% of net sales); Yasmin (11%); Magnevist (6%), and Ultravist (5%). ... $250.00 - Revere Reports - Revere Stroke; Stroke diagnosis, pharma, devices, and surgical intervention ... - Mar 8, 2005 The company's most important contrast media are Iopamiron and Ultravist. Both are nonionic products used in a wide range of indications in computer ... Pay-Per-View - Life Science Weekly - Factiva, from Dow Jones Merger and Acquisition Scenario - Aug 19, 2006 ...sold in the United States and Canada under the Betaseron trademark (16% of net sales); Yasmin (11%); Magnevist (6%), and Ultravist (5%). ... $250.00 - Revere Reports - Revere Merger and Acquisition Scenario - Nov 25, 2006 ...sold in the United States and Canada under the Betaseron trademark (16% of net sales); Yasmin (11%); Magnevist (6%), and Ultravist (5%). ... $250.00 - Revere Reports - Revere Merger and Acquisition Scenario - Nov 25, 2006 ...sold in the United States and Canada under the Betaseron trademark (16% of net sales); Yasmin (11%); Magnevist (6%), and Ultravist (5%). ... $250.00 - Revere Reports - Revere Merger and Acquisition Scenario - Nov 25, 2006 ...sold in the United States and Canada under the Betaseron trademark (16% of net sales); Yasmin (11%); Magnevist (6%), and Ultravist (5%). ... $250.00 - Revere Reports - Revere Merger and Acquisition Scenario - Nov 25, 2006 ...sold in the United States and Canada under the Betaseron trademark (16% of net sales); Yasmin (11%); Magnevist (6%), and Ultravist (5%). ... $250.00 - Revere Reports - Revere Merger and Acquisition Scenario - Nov 25, 2006 ...sold in the United States and Canada under the Betaseron trademark (16% of net sales); Yasmin (11%); Magnevist (6%), and Ultravist (5%). ... $250.00 - Revere Reports - Revere Schering AG sees 1st-qtr net profit rise 11%, with strong sales... - May 2, 2005 7% at 322.0 million euros, with Magnevist (gadopentic acid) rising 17% to 82.0 million euros and Ultravist (iopromide) 10% higher at 63.0 million euros. ... $4.95 - Pharma Marketletter - ECNext Merger and Acquisition Scenario - Nov 25, 2006 ...sold in the United States and Canada under the Betaseron trademark (16% of net sales); Yasmin (11%); Magnevist (6%), and Ultravist (5%). ... $250.00 - Revere Reports - Revere Merger and Acquisition Scenario - Nov 25, 2006 ...sold in the United States and Canada under the Betaseron trademark (16% of net sales); Yasmin (11%); Magnevist (6%), and Ultravist (5%). ... $250.00 - Revere Reports - Revere Merger and Acquisition Scenario - Nov 25, 2006 ...sold in the United States and Canada under the Betaseron trademark (16% of net sales); Yasmin (11%); Magnevist (6%), and Ultravist (5%). ... $250.00 - Revere Reports - Revere Merger and Acquisition Scenario - Sep 30, 2006 ...sold in the United States and Canada under the Betaseron trademark (16% of net sales); Yasmin (11%); Magnevist (6%), and Ultravist (5%). ... $250.00 - Revere Reports - Revere Merger and Acquisition Scenario - Nov 25, 2006 ...sold in the United States and Canada under the Betaseron trademark (16% of net sales); Yasmin (11%); Magnevist (6%), and Ultravist (5%). ... $250.00 - Revere Reports - Revere Drug/Medical Device - Sep 30, 2006 ...sold in the United States and Canada under the Betaseron trademark (16% of net sales); Yasmin (11%); Magnevist (6%), and Ultravist (5%). ... $70.00 - Revere Reports - Revere Press Release: Berlex, HPG Sign a Two-Year Sole Source Renewal … - Aug 4, 2005 ...to market two Berlex contrast media products in the U.S. Under terms ... hospital sales responsibility for Berlex's Magnevist and Ultravist imaging ... ... Pay-Per-View - PR Newswire - HighBeam Research Merger and Acquisition Scenario - Nov 25, 2006 ...sold in the United States and Canada under the Betaseron trademark (16% of net sales); Yasmin (11%); Magnevist (6%), and Ultravist (5%). ... $250.00 - Revere Reports - Revere Merger and Acquisition Scenario - Nov 25, 2006 ...sold in the United States and Canada under the Betaseron trademark (16% of net sales); Yasmin (11%); Magnevist (6%), and Ultravist (5%). ... $250.00 - Revere Reports - Revere Merger and Acquisition Scenario - Nov 25, 2006 ...sold in the United States and Canada under the Betaseron trademark (16% of net sales); Yasmin (11%); Magnevist (6%), and Ultravist (5%). ... $250.00 - Revere Reports - Revere Merger and Acquisition Scenario - Nov 25, 2006 ...sold in the United States and Canada under the Betaseron trademark (16% of net sales); Yasmin (11%); Magnevist (6%), and Ultravist (5%). ... $250.00 - Revere Reports - Revere Merger and Acquisition Scenario - Nov 25, 2006 ...sold in the United States and Canada under the Betaseron trademark (16% of net sales); Yasmin (11%); Magnevist (6%), and Ultravist (5%). ... $250.00 - Revere Reports - Revere |
|
Health Home | Conditions | Cancer | Medications | Surgery | Vaccines The Cancer News Network
COPYRIGHT 2009 CANCERNEWSNETWORK | Privacy |